Short Communication Otorhinolaryngology-Head and Neck Surgery

Juvenile-onset recurrent respiratory papillomatosis is a childhood disease notorious for its propensity for recurrence. The children are put through the trauma of repeated surgical procedures affecting the physical and emotional quality of life. Many adjuvant therapies are tried to prevent recurrence of the disease after surgical treatment. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor, which has been recently added to the armamentarium of adjuvant therapy. The present study tries to review the various studies in English literature evaluating the role of bevacizumab in Juvenile-onset recurrent respiratory papillomatosis. Correspondence to: Dr. Abdul Wadood Mohammed, Department of ENT, College of Medicine, King Faisal University, Al Ahsa, Kingdom of Saudi Arabia, E-mail: [email protected] , [email protected]